Ankleshwar, Gujarat, India, November 2025 — Cohance Lifesciences has appointed Rahul Pradhan as Vice President – Operations, where he will lead API Unit III in Ankleshwar. With more than 28 years of leadership experience in pharmaceutical manufacturing, he brings deep expertise in API operations, regulatory compliance, quality systems, and large-scale plant management across USFDA-approved and global regulatory facilities. In his new role, Rahul will focus on strengthening operational excellence, enhancing production capabilities, and supporting Cohance’s strategic growth in the Active Pharmaceutical Ingredient (API) segment.
Rahul most recently served as Vice President of Manufacturing at Zydus Group, where he led end-to-end operations and played a key role in improving capacity utilization, compliance robustness, and cost optimization across multiple manufacturing sites. His leadership contributed to operational stability and regulatory readiness across high-demand therapeutic portfolios.
Before joining Zydus, Rahul served as Vice President – Operations at Ipca Laboratories Limited, overseeing manufacturing and quality adherence for regulated market supply chains. Prior to that, he was associated with Aurobindo Pharma, where he led API manufacturing operations and process streamlining initiatives to support global market delivery.
Earlier in his career, Rahul held senior leadership roles at Dr. Reddy’s Laboratories as Director – Operations, General Manager – Production at Emcure Pharmaceuticals, and GM – Production at Hikal Ltd, where he drove multi-site production management, operational performance improvement, and cross-functional plant coordination.
His foundational years included production leadership roles at Cipla Ltd, Wockhardt Ltd, and Orchid, where he built his core expertise in plant operations, production planning, and compliance-driven execution in high-volume API environments. His journey reflects a strong commitment to operational rigor, efficiency, and quality-driven leadership.
Rahul’s appointment reinforces Cohance Lifesciences’ focus on operational excellence, quality assurance, and collaborative growth as the organization continues to scale its integrated CDMO and API capabilities for global partners.
About Cohance Lifesciences
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) is an integrated, technology-driven global CDMO platform focused on advancing novel and complex therapeutics. With a purpose anchored in collaboration and enhancement, Cohance partners with global pharmaceutical innovators to deliver scalable development, manufacturing, and commercialization support for APIs and intermediates. The organization combines scientific depth, operational excellence, and global quality frameworks to contribute to a healthier world.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
